Journal of Neuroimmunology
Volume 227, Issue 1 , Pages 35-43 , 8 October 2010

Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro

  • Ting Chang

      Affiliations

    • Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, China
    • These authors contributed equally to the present paper.
    • ,
  • Hong Lin

      Affiliations

    • Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, China
    • These authors contributed equally to the present paper.
    • ,
  • Jie Gao

      Affiliations

    • Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, China
    • These authors contributed equally to the present paper.
    • ,
  • Wei Li

      Affiliations

    • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
    • ,
  • Jiang Xu

      Affiliations

    • Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, China
    • ,
  • Chen Jing Sun

      Affiliations

    • Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, China
    • ,
  • Hang Li

      Affiliations

    • Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
    • ,
  • Fan Fan Li

      Affiliations

    • Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
    • ,
  • Yue Song

      Affiliations

    • Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
    • ,
  • Jing Ye

      Affiliations

    • Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
    • Corresponding Author InformationCorresponding authors. Tel./fax: +86 29 84777443.
    • ,
  • Zhu Yi Li

      Affiliations

    • Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710038, China
    • Corresponding Author InformationCorresponding authors. Tel./fax: +86 29 84777443.

Received 9 March 2010 ,Revised 30 May 2010 ,Accepted 3 June 2010.

References 

  1. Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J. Neurol. Neurosurg. Psychiatry. 2007;78:771
  2. Baerenwaldt A, Nimmerjahn F. Immune regulation: FcgammaRIIB-regulating the balance between protective and autoreactive immune responses. Immunol. Cell Biol. 2008;86:482–484
  3. Bournia VK, Vlachoyiannopoulos PG, Selmi C, Moutsopoulos HM, Gershwin ME. Recent advances in the treatment of systemic sclerosis. Clin. Rev. Allergy Immunol. 2009;36:176–200
  4. Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol. Ther. 2006;112:57–70
  5. Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. 2003;15:246–252
  6. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 2006;6:394–403
  7. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2006;2:20–27
  8. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann. NY Acad. Sci. 2008;1132:76–83
  9. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+anti-DNA plasma cells. Nat. Immunol. 2005;6:99–106
  10. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun. Rev. 2009;8:343–348
  11. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33:575–580
  12. Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, et al. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J. Neuroimmunol. 2008;201–202:90–94
  13. Kerkeni S, Marotte H, Miossec P. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve. 2008;38:1343–1345
  14. Li J, Tuzun E, Wu XR, Qi HB, Allman W, Saini SS, et al. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 2008;194:44–53
  15. Mihaylova N, Voynova E, Tchorbanov A, Nikolova M, Michova A, Todorov T, et al. Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor. Int. Immunol. 2008;20:165–175
  16. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008;8:34–47
  17. Proby CM, Ota T, Suzuki H, Koyasu S, Gamou S, Shimizu N, et al. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br. J. Dermatol. 2000;142:321–330
  18. Reiners KS, Hansen HP, Krussmann A, Schon G, Csernok E, Gross WL, et al. Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen. Immunology. 2004;112:228–236
  19. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs. 2006;66:1933–1948
  20. Tchorbanov AI, Voynova EN, Mihaylova NM, Todorov TA, Nikolova M, Yomtova VM, et al. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 2007;37:3587–3596
  21. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol. 2007;254:968–969
  22. Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 1982;79:188–192
  23. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J. Immunol. 1985;134:2343–2349
  24. Wu B, Goluszko E, Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2001;18;(Chapter 15, Unit 15)
  25. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J. Pediatr. 2003;143:674–677
  26. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology. 2000;55:1062–1063
  27. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med. 2002;8:518–521
  28. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med. 2005;11:446–449

PII: S0165-5728(10)00261-4

doi: 10.1016/j.jneuroim.2010.06.006

Journal of Neuroimmunology
Volume 227, Issue 1 , Pages 35-43 , 8 October 2010

Article Tools

* Image Usage & Resolution